Skip to main content
Journal cover image

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.

Publication ,  Journal Article
Bettencourt, MC; Bauer, JJ; Sesterhenn, IA; Mostofi, FK; McLeod, DG; Moul, JW
Published in: J Urol
September 1996

PURPOSE: We assessed the cellular proliferation of clinically localized prostate cancer by immunohistochemistry using the monoclonal antibody MIB to Ki-67 antigen in an attempt to identify associations between proliferative indexes and disease progression following radical prostatectomy. MATERIALS AND METHODS: Ki-67 proliferative antigen was evaluated using MIB 1 monoclonal antibody in archival paraffin embedded radical prostatectomy specimens from 180 patients followed for 1 to 9 years (mean 4.4). The percentage of tumor nuclei expressing Ki-67 antigen was measured and assigned and MIB 1 score (none or rare--negative, 1+--low score and 2 to 4+--high score) and analyzed for prostate specific antigen, stage, age, race, grade and serological recurrence postoperatively. RESULTS: There was a significant association between MIB 1 score and nuclear grade (p < 0.001), Gleason score (p < 0.001) and pathological stage (p = 0.01). Patients with a high MIB 1 score had earlier progression and a lower 5-year recurrence-free survival rate (44%) than those with negative MIB 1 scores (71%, p < 0.001). In multivariate Cox regression analysis with backward elimination, pathological stage (p < 0.01), pretreatment prostate specific antigen (p = 0.04) and MIB 1 score (p = 0.05) were statistically significant predictors of disease-free survival, and patients with a high MIB 1 score were 3.1 times as likely to have recurrence as those with a negative score. Controlling for stage, patients with organ confined disease and a high MIB 1 score had a lower 5-year disease-free survival rate (68%) than those with a low MIB 1 score (95%, p < 0.01). CONCLUSIONS: Proliferative activity as measured by the Ki-67 proliferative antigen, MIB 1, appears to be a prognostic marker of recurrent prostate cancer after radical prostatectomy.

Duke Scholars

Published In

J Urol

ISSN

0022-5347

Publication Date

September 1996

Volume

156

Issue

3

Start / End Page

1064 / 1068

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Prostatic Neoplasms
  • Prostatectomy
  • Prognosis
  • Nuclear Proteins
  • Neoplasm Recurrence, Local
  • Neoplasm Proteins
  • Multivariate Analysis
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bettencourt, M. C., Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., & Moul, J. W. (1996). Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol, 156(3), 1064–1068.
Bettencourt, M. C., J. J. Bauer, I. A. Sesterhenn, F. K. Mostofi, D. G. McLeod, and J. W. Moul. “Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.J Urol 156, no. 3 (September 1996): 1064–68.
Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996 Sep;156(3):1064–8.
Bettencourt, M. C., et al. “Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.J Urol, vol. 156, no. 3, Sept. 1996, pp. 1064–68.
Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996 Sep;156(3):1064–1068.
Journal cover image

Published In

J Urol

ISSN

0022-5347

Publication Date

September 1996

Volume

156

Issue

3

Start / End Page

1064 / 1068

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Prostatic Neoplasms
  • Prostatectomy
  • Prognosis
  • Nuclear Proteins
  • Neoplasm Recurrence, Local
  • Neoplasm Proteins
  • Multivariate Analysis
  • Middle Aged
  • Male